000			01913 a2200565 4500
005			20250514063728.0
264		0	_c20030424
008			200304s 0 0 eng d
022			_a0002-9343
024	7		_a10.1016/s0002-9343(02)01529-2 _2doi
040			_aNLM _beng _cNLM
100	1		_aGraham, David J
245	0	0	_aTroglitazone-induced liver failure: a case study. _h[electronic resource]
260			_bThe American journal of medicine _cMar 2003
300			_a299-306 p. _bdigital
500			_aPublication Type: Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAge Distribution
650	0	4	_aAged
650	0	4	_aChemical and Drug Induced Liver Injury _xepidemiology
650	0	4	_aChromans _xadministration & dosage
650	0	4	_aChronic Disease
650	0	4	_aConfidence Intervals
650	0	4	_aDiabetes Mellitus, Type 2 _xdrug therapy
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug and Narcotic Control
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aLiver Failure _xchemically induced
650	0	4	_aLiver Failure, Acute _xchemically induced
650	0	4	_aLiver Function Tests
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aOdds Ratio
650	0	4	_aProbability
650	0	4	_aRegistries
650	0	4	_aRisk Assessment
650	0	4	_aSeverity of Illness Index
650	0	4	_aSex Distribution
650	0	4	_aSurvival Rate
650	0	4	_aThiazoles _xadministration & dosage
650	0	4	_aThiazolidinediones
650	0	4	_aTroglitazone
650	0	4	_aUnited States
650	0	4	_aUnited States Food and Drug Administration
700	1		_aGreen, Lanh
700	1		_aSenior, John R
700	1		_aNourjah, Parivash
773	0		_tThe American journal of medicine _gvol. 114 _gno. 4 _gp. 299-306
856	4	0	_uhttps://doi.org/10.1016/s0002-9343(02)01529-2 _zAvailable from publisher's website
999			_c12473973 _d12473973